By specifically targeting patients with FRα‐high epithelial ovarian, fallopian tube, or peritoneal cancers, the trial shifts toward a more targeted treatment approach, focusing on FRα expression rather than solely on platinum sensitivity. This evidence concerns the gene FOLR1 and peritoneum cancer.